Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib plus Carboplatin in Metastatic Pancreatic Cancer
NCT00416793Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Dec 2006
- Primary completion
- Dec 2009
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in pancreatic cancer (PC), sponsored by National Cancer Institute. Primary endpoint: Overall Survival Rate at 6 Months. Started Dec 2006; status: terminated.
02
Drugs
bortezomib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00416793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00416793.